Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Archive

Hadassah Researcher Honored with Prestigious Prize for Blood Discovery

Dr. Abramovitch with Prof. Andreas Haupt, Chair of the ESA’s Research Committee. Photo Credit: ESA

Principal Investigator Dr. Rinat Abramovitch of the Hadassah Medical Organization’s Goldyne Savad Institute of Gene Therapy, has been awarded a grant from the European Society of Anesthesiology (ESA) for her work regarding the beneficial effect of using fresh blood for transfusions in surgery patients.

The €60,000 grant is awarded each year to only two recipients. Dr. Abramovitch’s study, entitled "Modifications of the Liver Regenerative Process as a Consequence of Bleeding and Transfusion of Red Blood Cells with Different Storage Time: Fresh vs. ‘Aged’," has thus far revealed that patients who lose blood during and after surgery for tumor excision do better with transfused blood that has just been donated, as opposed to blood that has been stored for a long time in the blood bank. “The liver regenerates better with newer blood,” Dr. Abramovitch explains. “No one knew that before.”

Her finding could, for example, affect the treatment of patients who undergo partial hepatectomy. "In these difficult times, when funding for research is hard to get,” comments Dr. Abramovitch, “this grant helps greatly to continue and deepen our study in the next three years. Of course, it is very flattering to get world recognition of the importance of our work by a European organization, in addition to the recognition and support received from the Chief Scientist of the Israeli Health Ministry."

Date: 7/3/2014


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America